福安药业(300194) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥467,678,211.11, a decrease of 42.22% compared to ¥809,399,726.88 in the same period last year[5] - Net profit attributable to shareholders was ¥69,049,030.79, down 43.63% from ¥122,500,109.56 year-on-year[5] - Basic earnings per share decreased by 40.00% to ¥0.06 from ¥0.10 in the same period last year[5] - Total operating revenue for the current period was ¥467,678,211.11, a decrease of 42.3% compared to ¥809,399,726.88 in the previous period[23] - Net profit for the current period was ¥68,797,738.97, a decline of 43.7% from ¥122,308,127.64 in the previous period[24] - Earnings per share (EPS) for the current period was ¥0.06, compared to ¥0.10 in the previous period[24] Cash Flow - The net cash flow from operating activities was ¥26,709,342.19, reflecting a significant decline of 82.72% compared to ¥154,573,579.14 in the previous year[5] - The net cash flow from operating activities was ¥26,709,342.19, a decrease of 82.7% compared to ¥154,573,579.14 in the previous period[26] - Cash inflow from investment activities totaled ¥86,378,451.79, significantly up from ¥15,389,382.34 in the prior period[26] - The net cash flow from financing activities increased by 266.50% to ¥16,917.59, compared to a negative cash flow of ¥10,160.58 in the previous year, mainly due to increased borrowings[13] - The net cash flow from financing activities was ¥169,175,907.54, a turnaround from a negative cash flow of -¥101,605,830.41 in the previous period[27] - Cash received from sales of goods and services was ¥491,427,553.85, down 34.8% from ¥754,433,823.99 in the last period[26] - The company incurred cash outflows for investment activities totaling ¥127,583,982.40, up from ¥111,433,578.13 in the previous period[26] - The cash flow from operating activities was impacted by a decrease in cash received from other operating activities, which fell to ¥13,039,956.14 from ¥21,803,368.25[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,079,333,135.54, an increase of 1.69% from ¥5,978,583,445.64 at the end of the previous year[5] - Non-current assets totaled ¥3,916,948,622.21, slightly up from ¥3,912,893,162.31 in the previous period[21] - Total liabilities increased to ¥1,631,825,116.90 from ¥1,580,455,675.99 in the previous period, reflecting a rise of 3.5%[21] - The company’s total assets increased to ¥6,079,333,135.54 from ¥5,978,583,445.64 in the previous period[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 42,286[15] - The largest shareholder, Wang Tianxiang, holds 24.00% of shares, totaling 285,499,420 shares[15] - The total number of shares held by the top 10 shareholders is significant, with the top shareholder holding 24%[15] - The company has not reported any changes in the number of restricted shares for major shareholders during the period[17] - There are no new developments regarding preferred shareholders or changes in their holdings[16] Expenses - The company reported a 72.09% reduction in selling expenses, down to ¥5,812.08 from ¥20,827.02, due to lower sales expenses associated with centralized procurement products[11] - Total operating costs decreased to ¥424,656,082.74, down 39.5% from ¥701,895,237.81 in the previous period[23] - Research and development expenses were ¥30,330,798.21, a decrease of 8.5% compared to ¥33,126,226.52 in the previous period[23] Other Financial Metrics - The company recorded a 106.14% increase in long-term borrowings, rising to ¥39,897.12 from ¥19,354.39, attributed to new loans taken during the period[9] - The company experienced a 31.95% decrease in other receivables, down to ¥1,130.45 from ¥1,661.09, primarily due to the receipt of demolition funds by a subsidiary[9] - The company's cash and cash equivalents increased to ¥978,778,701.76 from ¥846,314,302.70, representing a growth of approximately 15.6%[18] - Accounts receivable rose to ¥205,309,850.16 from ¥190,112,558.77, an increase of about 7.4%[18] - Inventory decreased to ¥797,858,517.97 from ¥850,972,090.66, a decline of approximately 6.2%[18] - Total current assets increased to ¥2,162,384,513.33 from ¥2,065,690,283.33, reflecting a growth of about 4.7%[18] - Long-term equity investments amounted to ¥1,057,236,103.83, up from ¥1,047,552,662.84, indicating a slight increase of about 0.2%[18] - Deferred income tax assets rose to ¥64,426,491.52 from ¥60,541,652.46, indicating a growth of 6.2%[21]